Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$2.51M$2.51M+139.4% vs Q3 2024 Net Income-$35.71M-$35.71MN/M vs Q3 2024 EPS Diluted-$0.28-$0.28N/M vs Q3 2024 Operating Income-$37,052,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,889,000N/M Margins · derivedOperating margin-1475.6%+1634.2 pt vs Q3 2024
Net margin-1422.1%+1427.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end